We are studying two cohorts of kidney transplant recipients, with the goal of defining specific clinicopathologic entities that cause late graft dysfunction: (1) prevalent patients with new onset late graft dysfunction (cross-sectional cohort); and (2) newly transplanted patients (prospective cohort). For the crosssectional cohort (n = 440), mean time from transplant to biopsy was 7.5 ± 6.1 years. Local pathology diagnoses included CAN (48%), CNI toxicity (30%), and perhaps surprisingly, acute rejection (cellular-or Abmediated) (23%). Actuarial rate of death-censored graft loss at 1 year postbiopsy was 17.7%; at 2 years, 29.8%. There was no difference in postbiopsy graft survival for recipients with versus without CAN (p = 0.9). Prospective cohort patients (n = 2427) developing graft dysfunction >3 months posttransplant undergo 'index' biopsy. The rate of index biopsy was 8.8% between 3 and 12 months, and 18.2% by 2 years. Mean time from transplant to index biopsy was 1.0 ± 0.6 years. Local pathology diagnoses included CAN (27%), and acute rejection (39%). Intervention to halt late graft deterioration cannot be developed in the absence of meaningful diagnostic entities. We found CAN in late posttransplant biopsies to be of no prognostic value. The DeKAF study will provide broadly applicable diagnostic information to serve as the basis for future trials.
 (1, 2) 
at least partially due to better 1-year function (3). The stability of long-term function (the slope of the GFR) has also improved perhaps due to superior control of rejection with newer protocols (4,5). In contrast, other large series, while noting a significant decrease in early rejection rates, have shown no significant improvement in long-term outcome (6,7).

There is no doubt that late graft loss continues to be a major challenge, with almost 4300 kidney transplant recipients returning to dialysis in the United States and Canada in 2005, most of them beyond 1 year after transplantation. Furthermore, improvements in graft survival have clearly plateaued with lower acute rejection rates and better early outcomes, but late graft loss remains an ongoing problem (8).
Determining the optimal treatment of recipients with late graft dysfunction (the troubled transplant) has been limited for a number of reasons: (a) deterioration of function can begin at any time following kidney transplantation and can be insidious; (b) there are likely many causes; (c) there are only a limited number of cases in any given year at a single institution; and, perhaps most importantly; (d) biopsy is usually done late in the clinical course (if at all), after the active phase of damage has occurred and only scar tissue is observable. The majority of these cases have been labeled 'chronic rejection,' 'chronic allograft nephropathy' (CAN) or, more recently, 'interstitial fibrosis and tubular atrophy, no evidence of any specific etiology' as represented by interstitial fibrosis and tubular atrophy (IF/TA) on biopsy (9).
However, these terms do not represent specific entities from an etiologic, physiologic or pathologic point of view. 
Data from the DeKAF Study
Prospective cohort recipients are enrolled at the time of kidney or simultaneous kidney-pancreas transplant (provided no other organs are transplanted; Table 1). At the time of transplant (and consent), clinical information is entered into the database; baseline serum creatinine level is determined at 3 months posttransplant. Those demonstrating subsequent deterioration of graft function (defined as ≥25% increase in serum creatinine level over baseline or new onset proteinuria) undergo biopsy (hereafter referred to as the 'index biopsy'). This cohort provides clinical information on all patients; there is a control group, without graft dysfunction, that is not biopsied. The prospective cohort was launched on October 1, 2005.
Data collection
Baseline creatinine level in the prospective cohort
To exclude the effects of permanent damage due to acute rejection, the creatinine reference point is reset for each participant 6 weeks after the initiation of therapy for acute rejection. The new value for the creatinine reference point is defined to be the average of up to three serum creatinine measurements taken at least 1 week apart and drawn between 6 and 12 weeks following initiation of treatment for acute rejection.
Clinical care
Allograft biopsies read by the local pathologist are used to guide clinical care according to local protocols.
Central pathology
Representative histologic sections (H&E, silver, PAS, trichrome stains and 11 unstained sections for additional studies) are submitted to a central laboratory for analysis. All biopsies were interpreted by the same pathologist (JG), using the Banff'97 classification (10). In addition, biopsies were scored for peritubular capillary infiltrates and for inflammation in areas of atrophy (iatr) and tubulitis in areas of atrophy (tatr). Scoring of peritubular capillary
Gourishankar et al. (7, 13, 14) . However, this observation provides no understanding of the etiology of the increased risk. Others have shown no relationship between serum creatinine level and the subsequent rate of deterioration of graft function over time (4, 15, 16 
At time of writing, a subset of biopsies have data available on centrally determined results for C4d positivity in peritubular capillaries (N = 325), peritubular capillary infiltrates (N = 289), and a score for inflammation and tubulitis in regions of tubular atrophy (N = 289
